Has John Cox, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,806 in general payments to John Cox, MD across 295 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Cox, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Cox, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Cox, MD

Radiation Oncology · Indianapolis, INNPI 1174796544

Payments from drug & device makers

$4,806in general payments, 2019–2025

Across 295 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$374
Novartis$354
Amgen$331
AstraZeneca$321
Incyte Corporation$239
Sanofi$204
plus $3K from 54 others

What the payments were for

Food & beverage$4,77099%
Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	24	$374
Novartis	21	$354
Amgen	22	$331
AstraZeneca(2 entities)	22	$321
Incyte Corporation	14	$239
Sanofi	10	$204
Pfizer	12	$192
Daiichi Sankyo Inc.	10	$173
E.r. Squibb & Sons, L.L.C.	11	$161
Seagen Inc.	10	$161
Johnson & Johnson(2 entities)	10	$159
Takeda Pharmaceuticals U.S.A., Inc.	6	$121
Eisai Inc.	7	$110
Lilly USA, LLC	6	$106
Ipsen Biopharmaceuticals, Inc	6	$101
Astellas Pharma US Inc	6	$91
Bristol Myers Squibb	5	$82
Bayer	6	$81
Boehringer Ingelheim	3	$79
Gilead	4	$73
Tersera Therapeutics LLC	4	$73
AbbVie	4	$67
Puma Biotechnology, Inc.	4	$66
Rigel Pharmaceuticals, Inc.	3	$54
Coherus Oncology, Inc.	3	$53
Regeneron Healthcare Solutions, Inc.	3	$51
Agios Pharmaceuticals, Inc.	3	$51
Acrotech Biopharma Inc.	3	$49
Genmab U.S., Inc.	3	$48
Stemline Therapeutics Inc.	2	$48
Genentech USA, Inc.	2	$45
Clovis Oncology, Inc.	3	$43
Pharmacyclics LLC, An Abbvie Company	3	$41
Morphosys, US Inc.	3	$40
AMAG Pharmaceuticals, Inc.	3	$36
Siemens Medical Solutions USA, Inc.	1	$30
Pharmacosmos Therapeutics Inc.	2	$30
Beigene USA, Inc.	2	$29
Servier Pharmaceuticals LLC	2	$29
Organon	2	$27
Foundation Medicine, Inc.	2	$27
ADC Therapeutics America, Inc.	2	$27
Acceleron Pharma, Inc.	2	$26
Cumberland Pharmaceuticals, Inc.	1	$23
TG Therapeutics, Inc.	1	$23
Blueprint Medicines Corporation	1	$23
Aadi Bioscience, Inc.	1	$19
Sumitomo Pharma America, Inc.	1	$17
G1 Therapeutics, Inc.	1	$17
Aurobindo Pharma USA, Inc.	1	$16
Mirati Therapeutics, Inc.	1	$16
Novocure Inc.	1	$15
Sobi, Inc	1	$15
AVEO Pharmaceuticals, Inc.	1	$14
Jazz Pharmaceuticals Inc.	1	$14
Emmaus Medical, Inc.	1	$14
Karyopharm Therapeutics Inc.	1	$14
Exelixis Inc.	1	$14
Dova Pharmaceuticals	1	$14
EMD Serono, Inc.	1	$14

How this compares

$4,806 in reported general payments places this provider in the 90th percentile of 116 radiation oncology providers in Indiana.

See all radiation oncology providers in Indiana →

Medicare billing

Part B allowed, 2024

$388,700

Medicare patients

172

Services billed

2,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	26	$230

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Indianapolis

Michael EatonIndianapolis$950K
Higinia CardenesIndianapolis$24K
Gordon WatsonIndianapolis$6K
Peter GarrettIndianapolis$5K
Garrett JensenIndianapolis$4K
Alexander YehIndianapolis$3K
Erin McCammackIndianapolis$2K
Zachary OaksIndianapolis$2K
David KimIndianapolis$2K
Darrel RossIndianapolis$2K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →